Astrazeneca Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Astrazeneca Plc (AZN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Astrazeneca Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 58,739M vs 791,417M combined for its competitors (6.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+42.1%) for its tracked peer group.
- Growth: Astrazeneca Plc generated 8.6% revenue growth year over year in Q4 2025, vs 8.2% for its competitors combined.
- Profitability: Its 17.4% net margin compares with 15.1% for the peer group.
- Scale: Astrazeneca Plc ranks #10 of 546 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 2.5% of industry market cap.
- Peer revenue share: Astrazeneca Plc accounted for 17.3% of combined revenue among its tracked peer group, up from 17.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.71M compares with $0.89M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AZN Sales vs. its Competitors, Q4 2025
Astrazeneca Plc reported revenue growth of 8.63 % year on year in Q4 2025, above its competitors' combined revenue growth of 8.22 %.
With a net margin of 17.42 %, Astrazeneca Plc achieved higher profitability than its competitors (15.10 %).
Astrazeneca Plc generated 17.28 % of the combined sales of its peer group, up from 17.23 % a year earlier.
Astrazeneca Plc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Astrazeneca Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Astrazeneca Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Astrazeneca Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (85) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Astrazeneca Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 8.6% for Astrazeneca Plc. Astrazeneca Plc's share of combined industry revenue moved from 11.26% to 11.23%, a loss of 0.03 percentage points.
Astrazeneca Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Astrazeneca Plc | Yes | Yes | Yes | No |
| Competitors combined (242) | ||||
| High-Confidence Competitors (107) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AZN Stock Performance relative to its Competitors
AZN Stock Performance relative to High-Confidence Competitors
AZN Stock Performance relative to Similar-Size Competitors
AZN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Cidara Therapeutics Inc | 282.9% | Outperformed |
| 3 | Chimerix Inc | 282.9% | Outperformed |
| 4 | Gt Biopharma Inc | 282.9% | Outperformed |
| 5 | Adlai Nortye Ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Astrazeneca Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Astrazeneca Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Astrazeneca Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Astrazeneca Plc |
291,859.70 | 58,739.00 |
 Eli Lilly And Company |
1,221,912.11 | 86,462.00 |
 Johnson and Johnson |
666,802.75 | 99,335.00 |
 Beone Medicines Ltd |
582,951.40 | 6,128.24 |
 Abbvie Inc |
510,761.28 | 66,014.00 |
 Merck and Co Inc |
362,843.00 | 66,569.00 |
| SUBTOTAL | 5,974,822.25 | 884,458.36 |
Sign in to see all competitors of Astrazeneca Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Astrazeneca Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Astrazeneca Plc's Competitors Named by the Company
Competitive relationships identified from Astrazeneca Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Verona Pharma Plc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Instil Bio Inc | Company report | 85% |
| Kronos Bio Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Ayala Pharmaceuticals Inc | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| IMAB | Company report | 85% |
| Actuate Therapeutics Inc | Company report | 85% |
| Genprex Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Os Therapies Incorporated | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Codexis inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Curis Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Compugen Ltd | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Tectonic Therapeutic Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Mineralys Therapeutics Inc | Company report | 85% |
| Contineum Therapeutics Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Arrivent Biopharma inc | Company report | 85% |
| BGNE | Company report | 85% |
| Cdt Equity Inc | Company report | 85% |
| Innoviva Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Nuvectis Pharma inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| INVO | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Celcuity Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Peak Bio Inc | Company report | 85% |
| Insmed Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| ENTO | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Context Therapeutics Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Atreca inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Centessa Pharmaceuticals Plc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Annexon Inc | Company report | 85% |
| Xoma Royalty Corporation | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Aptose Biosciences Inc | Company report | 85% |
| Infinity Pharmaceuticals Inc | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Bicycle Therapeutics Plc | Company report | 85% |
| G1 Therapeutics Inc | Company report | 85% |
| Amarin Corp Plcuk | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| Immunovant Inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Cidara Therapeutics Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Protara Therapeutics Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Rallybio Corporation | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Imunon Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Vivani Medical Inc | Company report | 85% |
| C4 Therapeutics Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Biocardia Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Valneva Se | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Intercept Pharmaceuticals inc | Company report | 85% |
| Spero Therapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Organon and Co | Company report | 85% |
| Sanofi | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
Company report basis, confidence, active dates and source counts for Astrazeneca Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Astrazeneca Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Astrazeneca Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Astrazeneca Plc | 291,860 | 706,847 | 123,141 |
| Eli Lilly And Company | 1,221,912 | 1,729,240 | 551,594 |
| Johnson and Johnson | 666,803 | 705,504 | 114,311 |
| Beone Medicines Ltd | 582,951 | 510,686 | 54,642 |
| Abbvie Inc | 510,761 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,843 | 887,587 | 42,267 |
| PEERS TOTAL | 5,682,963 | 891,141 | 114,365 |
Astrazeneca Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Astrazeneca Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 496 companies in Astrazeneca Plc's industry classification, broader than the peer set above. Market cap in millions of $.Astrazeneca Plc ranks #10 of 496 companies by market capitalization in its industry, holding 2.50 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,913 | 21.47 % |
| 2 | Johnson and Johnson | 681,032 | 11.41 % |
| 3 | Beone Medicines Ltd | 589,304 | 9.88 % |
| 4 | Abbvie Inc | 528,644 | 8.86 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 149,273 | 2.50 % |
Market cap and industry share for the rest of Astrazeneca Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Astrazeneca Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 5 | Merck and Co Inc | 375,021 | 81.05 % |
| 6 | Novartis Ag | 320,542 | 31.16 % |
| 7 | Abbott Laboratories | 202,029 | -7.86 % |
| 8 | Novo Nordisk A | 182,315 | -15.12 % |
| 9 | Pfizer Inc | 1,234 | 12.3% |
| 10 | Astrazeneca Plc | 149,273 | 17.71 % |
| 11 | Vertex Pharmaceuticals Inc | 1,234 | 12.3% |
| 12 | Bristol myers Squibb Company | 1,234 | 12.3% |
| 13 | Sanofi | 1,234 | 12.3% |
| 14 | Gsk Plc | 1,234 | 12.3% |
| 15 | Regeneron Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Astrazeneca Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Astrazeneca Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 81.90 % | 37.69 % (avg) | +44.2 pp |
| Operating Margin | 23.40 % | industry median | +19.1 pp |
| EBITDA Margin | 39.98 % | -6.49 % (avg) | +46.5 pp |
| Capital Intensity (Capex / Revenue) | 4.78 % | 7.58 % (avg) | -2.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Astrazeneca Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 26.5x | 26.6x | -0.1x |
| EV / EBITDA | 6.6x | 15.9x | -9.4x |
| P/B | 2.8x | 4.3x | -1.5x |
| Return on Equity | 21.00 % | industry aggregate | 0.88 % |
| Return on Invested Capital | 13.64 % | -9.93 % (avg) | 23.57 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Astrazeneca Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 3.29 % | 18.03 % | 8.63 % |
| Operating Margin | 17.88 % | 18.50 % | 23.40 % |
| Return on Invested Capital | 10.14 % | 11.82 % | 13.64 % |
| P/E | 16.2x | 15.1x | 26.5x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Astrazeneca Plc's Strategic Group Map
Astrazeneca Plc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Astrazeneca Plc's trailing-12-month revenue growth of 8.6% and operating margin of 23.4% compares with an average of 7.7% growth and 23.0% margin across its 8 closest peers by combined growth, margin and ROIC -- Astrazeneca Plc sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Astrazeneca Plc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Astrazeneca Plc falls in the Dog quadrant: relative market share of 0.12x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Astrazeneca Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.78 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Astrazeneca Plc's dedicated Suppliers and Customers pages, not here.
Astrazeneca Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Astrazeneca Plc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Astrazeneca Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 19.1 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.12x).
Opportunities
- Trades at a lower P/E than the industry average (26.5x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (50.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Astrazeneca Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Astrazeneca Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.1 % | +3.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Astrazeneca Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Astrazeneca Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Astrazeneca Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Astrazeneca Plc | 28.57 | 4.97 |
| Eli Lilly And Company | 44.41 | 14.13 |
| Johnson and Johnson | 41.20 | 6.71 |
| Beone Medicines Ltd | 880.11 | 95.13 |
| Abbvie Inc | 49.61 | 7.74 |
| Merck and Co Inc | 118.47 | 5.45 |
| PEERS AVERAGE | 51.42 | 6.76 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.